Vincristine for thrombotic thrombocytopenic purpura

O’Connor, Nathan; O’Shea, Michael; Hill, L. F.

doi:10.1016/0140-6736(92)91815-p

Cited by 17 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Steroids [1], intravenous immunoglobulins [33], vincristine [21,29], antiplatelet agents [7,32] and other drugs have been tried with variable success. Occasionally, splenectomy proved bene®cial for patients with recurrent disease [17,42] but has never been regarded as the therapy of choice.…”

Section: Discussionmentioning

confidence: 99%

New strategies in diagnosis and treatment of thrombotic thrombocytopenic purpura: case report and review

Häberle

Kehrel

Ritter

et al. 1999

European Journal of Pediatrics

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

New strategies in diagnosis and treatment of thrombotic thrombocytopenic purpura: case report and review

Häberle

Kehrel

Ritter

et al. 1999

European Journal of Pediatrics

View full text Add to dashboard Cite

show abstract

“…A single injection is usually administered, with an efficacy expected in less than a week and toxicities including cytopenias due to bone marrow depletion and peripheral neuropathy. 22 , 59 , 60 …”

Section: Adamts13 Supplementation: Therapeutic Plasma Exchangesmentioning

confidence: 99%

Unresponsive Thrombotic Thrombocytopenic Purpura (TTP): Challenges and Solutions

Lemiale¹,

Valade²,

Mariotte³

2021

TCRM

View full text Add to dashboard Cite

Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy secondary to a severely decreased A Disintegrin And Metalloprotease with ThromboSpondin type 1 repeats 13 (ADAMTS13) activity, resulting in the formation of widespread von Willebrand factor - and platelet-rich microthrombi. ADAMTS13 deficiency is mainly acquired through anti-ADAMTS13 autoantibodies in adults. With modern standards of care, unresponsive TTP has become rarer with a frequency of refractory/relapsing forms dropping from >40% to <10%. As patients with unresponsive TTP are at increased risk of mortality, prompt recognition and early therapeutic intensification are mandatory. Therapeutic options at the disposal of clinicians caring for patients with refractory TTP consist of increased ADAMTS13 supplementation, increased immunosuppression, and inhibition of von Willebrand factor adhesion to platelets. In this work, we focus on possible therapies for the management of patients with unresponsive TTP, and propose an algorithm for the management of these difficult cases.

show abstract

“…Vermutlich beeinflusst Vincristin die Affinität des Glykoproteins Ib auf der Oberfläche der Thrombozyten, das ei-nen Rezeptor für den von-Willebrand-Faktor darstellt [52]. Nach einer Latenz von 4-5 Tagen ist bei Therapieansprechen ein Thrombozytenanstieg zu erwarten [59,60]. Einige Autoren empfehlen den Einsatz von Vincristin, wenn nach 3 Tagen Behandlung mit Plasmaaustausch weiterhin eine geringe Thrombozytenzahl und eine hohe LDH auffällig sind [39].…”

Section: üBersichtunclassified

Thrombotisch-thrombozytopenische Purpura (Moschcowitz-Syndrom)

Chemnitz¹,

Schulz²,

Diehl³

et al. 2001

Med Klin

View full text Add to dashboard Cite

The therapy of choice is plasma exchange against fresh frozen plasma, whereupon the mortality could be dramatically reduced in the past decades. In case of treatment resistance to plasma exchange there exists no common treatment schedule. One therapy option is immunosuppressive treatment with corticosteroids and vincristine. In case of chronic relapsing TTP splenectomy should be discussed. In spite of severe thrombocytopenia substitution of thrombocytes is contraindicated.

show abstract

Vincristine for thrombotic thrombocytopenic purpura

Cited by 17 publications

References 0 publications

New strategies in diagnosis and treatment of thrombotic thrombocytopenic purpura: case report and review

New strategies in diagnosis and treatment of thrombotic thrombocytopenic purpura: case report and review

Unresponsive Thrombotic Thrombocytopenic Purpura (TTP): Challenges and Solutions

Thrombotisch-thrombozytopenische Purpura (Moschcowitz-Syndrom)

Contact Info

Product

Resources

About